

eInvest Better Future Fund (Managed Fund)

ASX:IMPQ
MONTHLY REPORT AUGUST 2022

	Month (%)	Quarter (%)	FYTD (%)	1 Year (%)	3 Year (%p.a)	Since Inception^ (% p.a.)	Since Inception Cumulative^ (%)
eInvest Better Future Fund (Managed Fund)	-2.9	-3.8	+6.6	-16.7	+7.4	+7.9	+28.5
S&P/ASX Small Ordinaries Accum. Index	+0.6	-2.6	+12.1	-14.7	+4.1	+3.8	+13.1
Value Added (Detracted)	-3.5	-1.2	-5.5	-2.0	+3.3	+4.1	+15.4

^Inception date was 23 May 2019. Performance shown above are net of fees. Fund returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

Overview

The benchmark rose by 0.6% in August, consolidating the bounce in July. IMPQ finished the month down 2.9%, underperforming the benchmark by 3.5%.

The underperformance was impacted by our positioning in the current environment. During August, the Resources component of the benchmark - which we are underweight - performed strongly, while the Healthcare component of the benchmark - which we are overweight - was weak. The Resources component of the benchmark finished up 6.0%, while the Healthcare component finished down 6.3%. We are comfortable with our position given the medium-term prospects of the stocks in these sectors, however, it held us back in August.

Positive contributors to relative performance this month included Nitro Software (+37.4%), AUB Group (+14.7%), Spark NZ (+6.6%) and NIB Holdings (+13.0%).


Negative contributors this month included Telix Pharmaceuticals (-16.1%), Immutep (-16.2%), Bendigo Bank (-12.2%), Smartgroup (-13.7%) and Pacific Edge (-39.4%).

eInvest Better Future Fund (Managed Fund)

The aim of IMPQ is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or conduct business in industries which have favourable characteristics having regard to ESG considerations. IMPQ seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index.

Portfolio Manager	IMPQ FUM
Damian Cottier	\$37 million
Distribution Frequency	Management Cost
Annually (if any)	0.99% (incl of GST and RITC)
Inception Date	+ performance fee
23 May 2019	

Portfolio's contribution to UN Sustainable Development Goals




Total Contribution: 67.33%
(equal to 54.83% social impact contribution and 12.5% environmental impact contribution)

Better Future Highlight

During August, portfolio holding 4D Medical announced the preliminary results of a clinical trial of the company's XV lung function scanning technology. The trial, which was conducted by Vanderbilt University Medical Center in Nashville, Tennessee, examined whether the technology is able to detect the presence of constrictive bronchiolitis ("CB") in US veterans who had been exposed to "burn pits" which were widely used by US Forces in the Middle East.

It is estimated that up to 3.5 million US veterans were exposed to harmful toxins from burn pits while deployed in operations post-2001. Preliminary analysis of data from the trial shows that 4D Medical's technology can detect CB in Veterans where traditional methods such as pulmonary function tests and CT scans failed to do so. Until now, highly invasive surgical biopsy has been the only way to diagnose CB. The US President recently signed into law a broad expansion of healthcare benefits for veterans exposed to toxic burn pits, including access to an additional US\$280 billion healthcare commitment over ten years. 4D Medical's technology has the potential to accelerate the diagnosis and treatment of the condition in these veterans.

Sector Active Exposure vs Index



Source: Data provided by the Sustainable Platform 31 August 2022; based on company revenues, based off the portfolio of the Better Future Fund

Fund Review

The benchmark rose by 0.6% in August, consolidating the bounce in July. IMPQ finished the month down 2.9%, underperforming the benchmark by 3.5%.

This outcome resulted from our positioning in the current environment. During August, the Resources component of the benchmark - which we are underweight - performed strongly while the Healthcare component of the benchmark - which we are overweight - was weak. The Resources component of the benchmark finished up 6.0%, while the Healthcare component finished down 6.3%. We are comfortable with our position given the medium-term prospects of the stocks in these sectors, however, it held us back in August.

It is over four years since the inception of the Trust. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception, the Fund has delivered a +7.9% p.a. return net of fees, outperforming the benchmark by +4.1% p.a.

Positive contributors to relative performance this month included Nitro Software (+37.4%), AUB Group (+14.7%), Spark NZ (+6.6%) and NIB Holdings (+13.0%).

Negative contributors this month included Telix Pharmaceuticals (-16.1%), Immutep (-16.2%), Bendigo Bank (-12.2%), Smartgroup (-13.7%) and Pacific Edge (-39.4%).

Nitro Software received an indicative proposal from a private equity consortium led by Potentia Capital to acquire the company at a 40% premium to the prior closing price.

AUB Group, Spark NZ and NIB Holdings each delivered a stronger than expected full year result and outlook statement.

Telix Pharmaceuticals was weaker after a strong performance last month and in the context of a result where cost growth was higher than expected as the company's commercial operations ramp up following the launch of the Illucix product.

Immutep was caught up in the weakness in the healthcare sector more broadly, while Bendigo Bank's outlook for net interest margin was weaker than the market's relatively high expectations. The Smartgroup result and outlook were also weaker than expected.

Pacific Edge announced that it had been notified of unexpected draft changes to aspects of the US Medicare reimbursement system which would result in the company's Cxbladder product not qualifying for US Medicare coverage. The changes do not impact other US clients such as Kaiser Permanente. While any implementation of the proposed changes would impact Pacific Edge's near-term progress, we continue to hold a small position in the company given the medium-term opportunity.

At month end, the portfolio held 47 stocks and cash of 8.9%.

At August end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Fund was 7.3 which is 28% higher than the benchmark ESGE Score of 5.7.

Contact Us

Level 27, 88 Phillip Street Sydney NSW 2000

1300 088 660

hello@invest.com.au

www.invest.com.au

The Responsible Entity is Perennial Investment Management Limited ABN 13 108 747 637, AFSL: 275101. The Investment Manager is Perennial Better Future Pty Limited ABN 45 647 633 065 | CAR 1293136 of Perennial Value Management Limited ABN 22 090 879 044, AFSL 247293. This report has been prepared by ETF Investments Australia Pty Ltd trading as elinvest Australia ("elinvest") ABN: 88 618 802 912, as the corporate authorised representative of Perennial Investment Management Limited. This report is for information purposes only. Accordingly, reliance should not be placed on this information as the basis for making an investment, financial or other decision. This information does not take into account your investment objectives, particular needs or financial situation. While every effort has been made to ensure the information is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. The current relevant product disclosure statement can be found at www.invest.com.au/IMPQ and you can find the IMPQ TMD at www.invest.com.au/targetmarketdeterminations/. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.

The rating issued 09/2021 published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. ©2022 Lonsec. All rights reserved.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned 02/2022) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <https://www.zenithpartners.com.au/RegulatoryGuidelines>

ESG Activity

Our ESG activity during the month included:

- Published the first Perennial Reconciliation Action Plan – Reflect RAP – the first stage of Reconciliation Australia's RAP framework. Read here: <https://perennial.net.au/perennial-launches-first-reconciliation-action-plan/>
- Met with HealthCo Healthcare & Wellness REIT and discussed GHG emissions and modern slavery, including key areas of risk.
- Discussed with Netwealth their Reconciliation journey, GHG emission disclosure (which they have now reported following engagement on the topic), cyber security, gender pay gap, employee share plans & turnover and cash fee rates.
- Engaged with APM Human Services on the details following their first Social Loan Linked corporate debt facility in Australia.
- Published a number of podcast episodes including: "Small Caps and ESG", "Sustainable Investment Flows" and "Greenwashing". Listen here: <https://perennial.net.au/perennial-better-podcast-series/>

Top 5 Portfolio Positions

	IMPQ	Index
Spark New Zealand Ltd	4.5%	0.5%
Meridian Energy Ltd	4.5%	0.0%
Sims Ltd	4.4%	1.1%
Chorus Ltd	3.9%	1.4%
Integral Diagnostics Ltd	3.8%	0.3%



Better Future and ESG Team

Damian Cottier – Portfolio Manager

Emilie O'Neill – Co-Head ESG & Equities Analyst